Cargando…

Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials

BACKGROUND: Interaction in clinical trials presents challenges for design and appropriate sample size estimation. Here we considered interaction between treatment assignment and a dichotomous prognostic factor with a continuous outcome. Our objectives were to describe differences in power and sample...

Descripción completa

Detalles Bibliográficos
Autores principales: Reichmann, William M, LaValley, Michael P, Gagnon, David R, Losina, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605155/
https://www.ncbi.nlm.nih.gov/pubmed/23414513
http://dx.doi.org/10.1186/1471-2288-13-21
_version_ 1782263832359469056
author Reichmann, William M
LaValley, Michael P
Gagnon, David R
Losina, Elena
author_facet Reichmann, William M
LaValley, Michael P
Gagnon, David R
Losina, Elena
author_sort Reichmann, William M
collection PubMed
description BACKGROUND: Interaction in clinical trials presents challenges for design and appropriate sample size estimation. Here we considered interaction between treatment assignment and a dichotomous prognostic factor with a continuous outcome. Our objectives were to describe differences in power and sample size requirements across alternative distributions of a prognostic factor and magnitudes of the interaction effect, describe the effect of misspecification of the distribution of the prognostic factor on the power to detect an interaction effect, and discuss and compare three methods of handling the misspecification of the prognostic factor distribution. METHODS: We examined the impact of the distribution of the dichotomous prognostic factor on power and sample size for the interaction effect using traditional one-stage sample size calculation. We varied the magnitude of the interaction effect, the distribution of the prognostic factor, and the magnitude and direction of the misspecification of the distribution of the prognostic factor. We compared quota sampling, modified quota sampling, and sample size re-estimation using conditional power as three strategies for ensuring adequate power and type I error in the presence of a misspecification of the prognostic factor distribution. RESULTS: The sample size required to detect an interaction effect with 80% power increases as the distribution of the prognostic factor becomes less balanced. Misspecification such that the actual distribution of the prognostic factor was more skewed than planned led to a decrease in power with the greatest loss in power seen as the distribution of the prognostic factor became less balanced. Quota sampling was able to maintain the empirical power at 80% and the empirical type I error at 5%. The performance of the modified quota sampling procedure was related to the percentage of trials switching the quota sampling scheme. Sample size re-estimation using conditional power was able to improve the empirical power under negative misspecifications (i.e. skewed distributions) but it was not able to reach the target of 80% in all situations. CONCLUSIONS: Misspecifying the distribution of a dichotomous prognostic factor can greatly impact power to detect an interaction effect. Modified quota sampling and sample size re-estimation using conditional power improve the power when the distribution of the prognostic factor is misspecified. Quota sampling is simple and can prevent misspecification of the prognostic factor, while maintaining power and type I error.
format Online
Article
Text
id pubmed-3605155
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36051552013-03-26 Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials Reichmann, William M LaValley, Michael P Gagnon, David R Losina, Elena BMC Med Res Methodol Research Article BACKGROUND: Interaction in clinical trials presents challenges for design and appropriate sample size estimation. Here we considered interaction between treatment assignment and a dichotomous prognostic factor with a continuous outcome. Our objectives were to describe differences in power and sample size requirements across alternative distributions of a prognostic factor and magnitudes of the interaction effect, describe the effect of misspecification of the distribution of the prognostic factor on the power to detect an interaction effect, and discuss and compare three methods of handling the misspecification of the prognostic factor distribution. METHODS: We examined the impact of the distribution of the dichotomous prognostic factor on power and sample size for the interaction effect using traditional one-stage sample size calculation. We varied the magnitude of the interaction effect, the distribution of the prognostic factor, and the magnitude and direction of the misspecification of the distribution of the prognostic factor. We compared quota sampling, modified quota sampling, and sample size re-estimation using conditional power as three strategies for ensuring adequate power and type I error in the presence of a misspecification of the prognostic factor distribution. RESULTS: The sample size required to detect an interaction effect with 80% power increases as the distribution of the prognostic factor becomes less balanced. Misspecification such that the actual distribution of the prognostic factor was more skewed than planned led to a decrease in power with the greatest loss in power seen as the distribution of the prognostic factor became less balanced. Quota sampling was able to maintain the empirical power at 80% and the empirical type I error at 5%. The performance of the modified quota sampling procedure was related to the percentage of trials switching the quota sampling scheme. Sample size re-estimation using conditional power was able to improve the empirical power under negative misspecifications (i.e. skewed distributions) but it was not able to reach the target of 80% in all situations. CONCLUSIONS: Misspecifying the distribution of a dichotomous prognostic factor can greatly impact power to detect an interaction effect. Modified quota sampling and sample size re-estimation using conditional power improve the power when the distribution of the prognostic factor is misspecified. Quota sampling is simple and can prevent misspecification of the prognostic factor, while maintaining power and type I error. BioMed Central 2013-02-15 /pmc/articles/PMC3605155/ /pubmed/23414513 http://dx.doi.org/10.1186/1471-2288-13-21 Text en Copyright ©2013 Reichmann et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Reichmann, William M
LaValley, Michael P
Gagnon, David R
Losina, Elena
Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials
title Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials
title_full Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials
title_fullStr Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials
title_full_unstemmed Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials
title_short Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials
title_sort impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605155/
https://www.ncbi.nlm.nih.gov/pubmed/23414513
http://dx.doi.org/10.1186/1471-2288-13-21
work_keys_str_mv AT reichmannwilliamm impactofmisspecifyingthedistributionofaprognosticfactoronpowerandsamplesizefortestingtreatmentinteractionsinclinicaltrials
AT lavalleymichaelp impactofmisspecifyingthedistributionofaprognosticfactoronpowerandsamplesizefortestingtreatmentinteractionsinclinicaltrials
AT gagnondavidr impactofmisspecifyingthedistributionofaprognosticfactoronpowerandsamplesizefortestingtreatmentinteractionsinclinicaltrials
AT losinaelena impactofmisspecifyingthedistributionofaprognosticfactoronpowerandsamplesizefortestingtreatmentinteractionsinclinicaltrials